TaiMed Biologics Inc. (4147.TWO)
TWD 82.5
(-0.48%)
TWD 82.5
(-0.48%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -25.6 Million | -605.21 Million | -211.27 Million | -201.93 Million | -655.31 Million | -522.85 Million |
| Net Income | -194.81 Million | -269.28 Million | -470.93 Million | -183.3 Million | -578.65 Million | -321.71 Million |
| Depreciation & Amortization | 155.38 Million | 156.44 Million | 156.66 Million | 139.78 Million | 92.53 Million | 62.9 Million |
| Deferred income taxes | 25.46 Million | - | 18.86 Million | 58.4 Million | 232.2 Million | 38.97 Million |
| Stock-based compensation | 10.51 Million | 12.26 Million | 10.22 Million | 16.68 Million | 27.37 Million | 25.48 Million |
| Change in working capital | -31.55 Million | -796.28 Million | -6.02 Million | -230.56 Million | -457.63 Million | -128.35 Million |
| Other non-cash items | 9.4 Million | 291.65 Million | 79.93 Million | -2.93 Million | 28.85 Million | -200.15 Million |
| Investing Cash Flow | -16.45 Million | 106.11 Million | 190.92 Million | -109.16 Million | 366.71 Million | -684.24 Million |
| Investments in PPE | -6.15 Million | -4.76 Million | -13.56 Million | -384.52 Million | -137.83 Million | -1.18 Billion |
| Acquisitions | - | - | 3.87 Million | 332.15 Million | - | 338.75 Million |
| Investment purchases | -43.38 Million | - | -18.23 Million | -16.61 Million | - | -8.48 Million |
| Sales/Maturities of investments | 30.5 Million | 110.87 Million | 222.3 Million | 289.97 Million | 504.37 Million | 508.8 Million |
| Other Investing Activities | 2.58 Million | 109.67 Million | -3.46 Million | -330.15 Million | 166 Thousand | -338.17 Million |
| Financing Cash Flow | 19.23 Million | 208.38 Million | 2.78 Million | 536.03 Million | 57.92 Million | 93.53 Million |
| Debt repayment | -13.99 Million | -200 Million | -1.92 Million | -536 Million | -1.82 Million | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | 35.27 Million | 10.3 Million | 4.7 Million | 1.94 Million | 59.74 Million | 93.53 Million |
| Other Financing Activities | -2.05 Million | 398.07 Million | -1.91 Million | 1.07 Billion | -1.82 Million | 93.53 Million |
| Accounts receivables | -44.99 Million | 72.3 Million | 86.06 Million | -43.03 Million | -111.85 Million | -99.02 Million |
| Accounts payables | 13.4 Million | -122.49 Million | 116.78 Million | -130.23 Million | -13.69 Million | 149.86 Million |
| Inventory | 110.85 Million | -382.84 Million | 14.83 Million | -384.98 Million | -538.71 Million | -198.46 Million |
| Other working capital | -110.82 Million | -363.25 Million | -223.71 Million | 327.69 Million | 206.62 Million | 70.11 Million |
| Cash at beginning of period | 274.11 Million | 551.61 Million | 572.09 Million | 352.93 Million | 586.09 Million | 1.69 Billion |
| Cash at end of period | 251 Million | 274.11 Million | 551.61 Million | 572.09 Million | 352.93 Million | 586.09 Million |
| Capital Expenditure | -6.15 Million | -4.76 Million | -13.56 Million | -384.52 Million | -137.83 Million | -1.18 Billion |
| Effect of forex changes on cash | -279 Thousand | 13.2 Million | -2.9 Million | -5.78 Million | -2.47 Million | 2.53 Million |
| Net cash flow / Change in cash | -23.1 Million | -277.5 Million | -20.47 Million | 219.15 Million | -233.15 Million | -1.11 Billion |
| Free Cash Flow | -31.75 Million | -609.97 Million | -224.83 Million | -586.46 Million | -793.14 Million | -1.7 Billion |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -27.53 Million | -16.03 Million | -60.28 Million | -194.81 Million | -5.87 Million | -47.84 Million |
| Depreciation & Amortization | 38.5 Million | 38.6 Million | 38.73 Million | 155.38 Million | 38.7 Million | 38.82 Million |
| Deferred income taxes | - | - | 5.07 Million | 25.46 Million | 21.25 Million | -5.17 Million |
| Stock-based compensation | 3.2 Million | 17.46 Million | 1.4 Million | 10.51 Million | 3.03 Million | 3.03 Million |
| Change in working capital | 43.21 Million | -40.86 Million | 45.46 Million | -31.55 Million | -44.87 Million | 19.16 Million |
| Other non-cash items | -726 Thousand | 118.37 Million | -1.47 Million | 9.4 Million | 2 Million | 7.22 Million |
| Investing Cash Flow | -1.08 Billion | -59.93 Million | -28.92 Million | -16.45 Million | -109.27 Million | 93 Million |
| Investments in PPE | -534 Thousand | -857 Thousand | -2.14 Million | -6.15 Million | -849 Thousand | -2.93 Million |
| Acquisitions | - | - | - | - | 8.09 Million | - |
| Investment purchases | -1.07 Billion | -58.98 Million | -35.28 Million | -43.38 Million | -8.09 Million | - |
| Sales/Maturities of investments | - | - | 8.92 Million | 30.5 Million | -100.33 Million | 91.59 Million |
| Other Investing Activities | -8000.00 | -90 Thousand | -420 Thousand | 2.58 Million | -8.09 Million | 4.34 Million |
| Financing Cash Flow | -211.48 Million | 1.63 Billion | -6.36 Million | 19.23 Million | -2.29 Million | 19.69 Million |
| Debt repayment | -206.64 Million | -6.69 Million | -6.65 Million | -13.99 Million | -6.62 Million | -715 Thousand |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | -4.27 Million | 1.64 Billion | 832 Thousand | 35.27 Million | 4.83 Million | 20.91 Million |
| Other Financing Activities | -204.27 Million | 1.64 Billion | -542 Thousand | -2.05 Million | -505 Thousand | -503 Thousand |
| Accounts receivables | 27.3 Million | -16.24 Million | 37.44 Million | -44.99 Million | -59.5 Million | 49.14 Million |
| Accounts payables | -8.23 Million | -2.92 Million | -11.56 Million | 13.4 Million | 17.01 Million | 7.77 Million |
| Inventory | 53.83 Million | 23.68 Million | 80.57 Million | 110.85 Million | 3.02 Million | 18.62 Million |
| Other working capital | -29.68 Million | -45.38 Million | -60.99 Million | -110.82 Million | -5.41 Million | -56.39 Million |
| Cash at beginning of period | 1.86 Billion | 251 Million | 265.31 Million | 274.11 Million | 357.18 Million | 225.9 Million |
| Cash at end of period | 616.18 Million | 1.86 Billion | 251 Million | 251 Million | 265.31 Million | 357.18 Million |
| Capital Expenditure | -534 Thousand | -857 Thousand | -2.14 Million | -6.15 Million | -849 Thousand | -2.93 Million |
| Effect of forex changes on cash | 2.67 Million | 7.08 Million | -7.91 Million | -279 Thousand | 5.45 Million | 3.33 Million |
| Net cash flow / Change in cash | -1.24 Billion | 1.61 Billion | -14.3 Million | -23.1 Million | -91.86 Million | 131.27 Million |
| Free Cash Flow | 48.81 Million | 26.53 Million | 26.76 Million | -31.75 Million | 13.39 Million | 12.3 Million |
DLHC
AMIGF
AET
7337
ZKIN
4130